133 results on '"Corvaia, Nathalie"'
Search Results
2. 1304 Robust machine learning (ML) approach for screening microbiome ecosystem therapies (MET) drug candidates in combination with immune checkpoint inhibitors
3. 1321 Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
4. Development of a fast workflow to screen the charge variants of therapeutic antibodies
5. Data from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
6. Table S1, Table S2, Table S3, Table S4, Figure S1Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7 from Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
7. A new anti-human Fc method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in serum from pre-clinical species
8. Structural Characterization of Antibodies by Mass Spectrometry
9. Antibody Glycans Characterization
10. A JAM-A–tetraspanin–αvβ5 integrin complex regulates contact inhibition of locomotion
11. Safety and Immunogenicity of a Novel Recombinant Subunit Respiratory Syncytial Virus Vaccine (BBG2Na) in Healthy Young Adults
12. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody
13. Challenge of BALB/c Mice with Respiratory Syncytial Virus Does Not Enhance the Th2 Pathway Induced after Immunization with a Recombinant G Fusion Protein, BBG2NA, in Aluminum Hydroxide
14. The way forward, enhanced characterization of therapeutic antibody glycosylation: Comparison of three level mass spectrometry-based strategies
15. Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS
16. A novel role for junctional adhesion molecule-A in tumor proliferation: Modulation by an anti-JAM-A monoclonal antibody
17. Abstract 4054: Development of a new site-specific sulfomaleimide rebridging platform for the generation of homogeneous, stable, potent and safe antibody drug conjugates
18. Efficacy of the Antibody–Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
19. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells
20. Complexity and Complementarity of Outer Membrane Protein A Recognition by Cellular and Humoral Innate Immunity Receptors
21. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate
22. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against Respiratory Syncytial Virus (RSV)
23. Passive Transfer of Serum Antibodies Induced by BBG2Na, a Subunit Vaccine, in the Elderly Protects SCID Mouse Lungs Against Respiratory Syncytial Virus Challenge
24. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine
25. Streptococcus pneumoniae polysaccharides conjugated to the outer membrane protein A from Klebsiella pneumoniae elicit protective antibodies
26. Differential Effects of Parainfluenza Virus Type 3 on Human Monocytes and Dendritic Cells
27. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine
28. Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein
29. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na
30. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate
31. Abstract 815: New approach for old target: W0101 antibody drug conjugate effectively inhibits tumor growth in preclinical models of IGF-1R overexpressing solid tumors
32. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130–230 RSV-A protein
33. Additional file 1: Table S1. of Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
34. Additional file 4: Figure S2. of Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
35. Additional file 3: Figure S1. of Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
36. Additional file 2: of Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
37. Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC–MS analysis
38. Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches
39. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells
40. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
41. Insulin-like growth factor receptor type I as a target for cancer therapy
42. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
43. A novel role for junctional adhesion molecule-A in tumor proliferation: Modulation by an anti-JAM-A monoclonal antibody
44. The Respiratory Syncytial Virus G Protein Conserved Domain Induces a Persistent and Protective Antibody Response in Rodents
45. Abstract C56: Characterization of hz515H7, a novel humanized anti-CXCR4 antibody: In vitro efficacy on CXCR4-associated signaling pathways and in vivo antitumor activity.
46. Abstract 4571: 515H7, a novel anti-CXCR4 antibody: In vitro efficacy on CXCR4-associated signaling pathways and in vivo anti-tumor activity
47. Abstract 4580: A novel role for Junctional Adhesion Molecule-A (JAM-A) in tumor proliferation: modulation by a humanized anti-JAM-A monoclonal antibody
48. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy
49. Effect of microtubule-targeting drugs on cell–cell and cell–matrix junctions in tumor epithelial cells
50. Strategies and challenges for the next generation of therapeutic antibodies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.